Spineway (ALSPW) Q3 2025 TU earnings summary

Executive summary

• Q3 2025 revenue reached €3.0 million, an 18% increase year-over-year, driven by deferred orders from major accounts.

• Premium product ranges led sales acceleration, helping offset earlier shortfalls despite supply chain challenges.

Financial highlights

• Q3 2025 revenue: €3.0 million, up from €2.6 million in Q3 2024 (+18%).

• Nine-month 2025 revenue: €8.6 million, down 5% compared to the same period in 2024.

• Q2 2025 revenue: €2.7 million (down 21% year-over-year); Q1 2025 revenue: €2.8 million (down 8% year-over-year).

Outlook and guidance

• Strategic focus remains on global recognition in less invasive spine treatments, supported by strong Q3 performance.

• Next financial update scheduled for January 13, 2026, covering full-year 2025 revenue.